AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $223.67. The company's market cap stands at 395.19B, with a P/E ratio of 171.62 and a dividend yield of 2.9%.
On 2025-12-16, AbbVie(ABBV) stock moved within a range of $221.91 to $227.96. With shares now at $223.67, the stock is trading +0.8% above its intraday low and -1.9% below the session's peak.
Trading volume for AbbVie(ABBV) stock has reached 6.33M, versus its average volume of 5.16M.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
ABBV News
BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, which sees “a relatively clean setup...
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model ba...
Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and...
Analyst ratings
70%
of 30 ratingsMore ABBV News
Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and...
Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and...
Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and...
Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and...
In early December 2025, OSE Immunotherapeutics amended its partnership with AbbVie on the pre-clinical anti-inflammatory antibody ABBV-230, taking back responsi...
Key Points With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly is growing its top line incredibly r...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Building wealth...
